Three new US Patents for the Australian Life Science sector

252 Life Science patents (classification A61K) were issued by the US Patent and Trademark Office on Tuesday 13 September 2016 (click here):

US Patent 9,439,946 has been granted to CSL for Reconstituted high density lipoprotein formulation and production method thereof. This patent covers CSL's reconstituted HDL, useful for the treatment of Acute Coronary Syndrome.

US Patent 9,440,926 has been granted to Biotron (ASX: BIT) for  Antiviral compounds and methods. This patent covers antiviral compounds that target the p7 protein of HCV.

US Patent 9,441,239 has been granted to the CSIRO for Methods and means for obtaining modified phenotypes.  This patent covers the CSIRO's gene silencing technology, which involves double-stranded RNA.

​Over the last twelve months the Australian Life Science sector has been granted 121 US patents, versus 130 in the previous corresponding period.